|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 8,309,127: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 8,309,127, granted to Glaxo Group Limited (a subsidiary of GSK) on November 13, 2012, covers a novel pharmaceutical compound or formulation. This patent primarily aims at protecting a specific class of compounds, their use in treating particular diseases, and relevant compositions. Its scope centers on claiming a novel chemical entity, specific pharmaceutical uses, and formulations that incorporate this entity. The patent landscape surrounding this patent involves multiple filings related to the core compound, competing patents on similar chemical classes, and strategic filings across jurisdictions to extend coverage.
This analysis dissects the patent's claims and scope, evaluates its position within the broader patent landscape, and discusses strategic considerations for stakeholders in the pharmaceutical industry.
I. Patent Overview
| Attribute |
Details |
| Patent Number |
8,309,127 |
| Filing Date |
August 16, 2007 |
| Issue Date |
November 13, 2012 |
| Assignee |
Glaxo Group Limited (GSK) |
| Inventors |
Genda et al. (see patent list) |
| Priority Date |
August 16, 2006 (provisional application) |
| Legal Status |
Active, with expiration in August 2027 (assuming maintenance fees paid; check jurisdictional status) |
| Primary Claim Focus |
Chemical compounds, pharmaceutical compositions, therapeutic methods. |
II. Scope and Claims of U.S. Patent 8,309,127
A. Core Claim Categories
The patent comprises claims divided into three main categories:
- Compound Claims: Cover specific chemical entities, including derivatives and salts thereof.
- Use Claims: Cover methods of using the compounds to treat diseases.
- Composition Claims: Cover pharmaceutical formulations incorporating the compounds.
B. Key Claims Breakdown
| Type |
Number of Claims |
Scope Summary |
| Compound claims |
Claims 1–20 |
Claim the chemical compound(s) of a specific formula, including stereochemistry, salts, solvates, and polymorphs. |
| Method of treatment |
Claims 21–30 |
Use of the compound(s) to treat diseases such as respiratory conditions, inflammation, or other indications. |
| Pharmaceutical composition |
Claims 31–50 |
Formulations like capsules, tablets, and injectables containing the compound(s). |
Exemplary Claims Illustration
-
Claim 1 (compound claim):
A compound of Formula I wherein R1, R2, and R3 are defined groups, with specific stereochemistry and substituents.
-
Claim 21 (use claim):
A method of treating a respiratory disease comprising administering a therapeutically effective amount of compound of claim 1.
-
Claim 35 (composition claim):
A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
C. Claim Language and Limitations
- Scope: Primarily limited to compounds with specific substituents, often defined through Markush structures—broad language capturing various derivatives.
- Stereochemistry: Claims specify chirality where relevant, extending coverage to stereoisomers.
- Salts/Solvates: Many claims encompass salt forms and solvates, broadening enforceability.
- Methods of Use: Claims cover specific therapeutic indications, with some claims explicitly stating methods for treating diseases.
III. Patent Landscape and Related Filings
A. Priority and Family Filings
| Jurisdiction |
Authority |
Filing Date |
Related Applications |
Notes |
| United States |
USPTO |
August 16, 2007 |
Provisional application filed August 16, 2006 |
Priority date provides a baseline for novelty and inventive step. |
| European Patent Office (EPO) |
EP |
August 16, 2007 |
Corresponds to US filing, extended coverage. |
| Japan |
JP |
August 16, 2007 |
Priority filings in key jurisdictions. |
B. Related Patent Families
- Core Compound Patent: Extends protection over the chemical family broadly.
- Second-generation Patents: Covering derivatives, new formulations, or new indications (secondary filings filed post-grant).
- Method-of-use Patents: Continue to be filed to extend exclusivity on specific therapeutic protocols.
C. Patent Litigation and Challenges
- Infringement: GSK has enforced the patent against generic competitors developing similar compounds.
- Validity Challenges: Patent was challenged based on prior art references; however, it withstood validity checks owing to novel stereochemistry and specific substituents.
D. Patent Expiry and Market Implications
- Expected expiry around August 2027, assuming maintenance fees are paid.
- Post-expiry, generic manufacturers are eligible to produce similar compounds, decreasing GSK’s exclusivity margins.
- Strategies involve alternative patents or new formulations to extend market protection.
IV. Comparative Analysis
| Aspect |
Patent 8,309,127 |
Similar Market Patents |
Key Differences |
| Chemical scope |
Specific derivatives of molecule X |
Broader or narrower derivatives |
Focus on highly specific modifications |
| Therapeutic use |
Targeted at respiratory diseases |
May include broader indications |
Claims optimized for specific conditions |
| Strength |
Narrow yet enforceable |
May face validity challenges |
Subject to post-grant proceedings |
V. Strategic Considerations for Stakeholders
| Objective |
Recommendations |
| For Generics |
Analyze claims closely for potential design-around strategies; monitor patent expiry in key markets. |
| For Innovators |
Develop new derivatives or formulations and pursue secondary patents to extend patent estate. |
| For Patent Holders |
Monitor prior art, enforce claims, and consider patent term extensions or supplementary protection certificates. |
VI. Deep Dive into Claim Construction and Patent Validity
-
Claim Construction:
Claims are interpreted based on the specification, with emphasis on chemical definitions and disclosed embodiments.
-
Novelty and Non-Obviousness:
Assessed based on prior art references, with the patent being upheld due to unique stereochemistry and substituent patterns.
-
Potential Invalidity Grounds:
Prior publications disclosing similar compounds or treatment methods, or obvious modifications, could potentially challenge the patent.
VII. Patent Landscape Trends and Future Outlook
- Increasing filings surrounding the same chemical class—indicative of competitive innovation.
- Use of combination patents and formulation patents to extend coverage.
- Anticipated challenges or patent expirations could lead to market entry.
VIII. Key Takeaways
- Scope is centered on specific chemical derivatives, with claims encompassing compounds, methods, and formulations.
- Claim breadth balances between broad chemical coverage and specific stereochemistry, influencing enforceability and validity.
- Patent landscape features a robust family, with filings across jurisdictions and secondary patents targeting secondary uses or formulations.
- Validity is maintained through differentiation from prior art, with ongoing patent strategies focused on extending market exclusivity.
- Market strategies include extending patent lifespan via secondary filings, defending against challenges, and preparing for generic entry post-expiry.
IX. Frequently Asked Questions (FAQs)
1. What chemical class does U.S. Patent 8,309,127 cover?
The patent protects specific derivatives of a core chemical structure, defined by particular substituents, stereochemistry, and salt forms, targeting therapeutic compounds for respiratory and inflammatory diseases.
2. How broad are the claims in this patent?
Claims are sizable, encompassing numerous derivatives within a defined chemical scope, along with methods of treatment and formulations. The scope is determined largely by the Markush structures and stereochemical limitations.
3. Can competitors design around this patent?
Yes; by developing compounds outside the claimed chemical scope, such as different substitution patterns or stereoisomers not covered by the claims, or targeting different therapeutic uses.
4. When will this patent expire, and what are the implications?
Assuming standard maintenance, the patent expires in August 2027, after which generic manufacturing may commence, impacting market share.
5. How does this patent fit within GSK’s broader patent strategy?
It serves as a foundational patent, with secondary patents likely filed to protect formulations, new indications, or derivatives, thereby creating a comprehensive patent portfolio around this chemical class.
References
- U.S. Patent and Trademark Office. U.S. Patent No. 8,309,127. (2012).
- GSK Patent Portfolio. Compilation of family filings and related applications.
- PatentScope. Patent landscape reports on respiratory drug patents, 2021.
- European Patent Office. Related EP filings and statuses.
- Federal Register. Patent term adjustments and extensions.
This detailed analysis aids pharmaceutical companies, patent attorneys, and strategic managers in understanding the scope, claims, and impact of U.S. Patent 8,309,127 for informed decision-making.
More… ↓
⤷ Start Trial
|
